| 5.64 -0.51 (-8.29%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.8  |
1-year : | 9.11 |
| Resists | First : | 6.67 |
Second : | 7.8 |
| Pivot price | 5.38 |
|||
| Supports | First : | 4.98 |
Second : | 3.94 |
| MAs | MA(5) : | 6 |
MA(20) : | 5.11 |
| MA(100) : | 5.11 |
MA(250) : | 6.23 |
|
| MACD | MACD : | 0.4 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 79.5 |
D(3) : | 85.5 |
| RSI | RSI(14): 56.9 |
|||
| 52-week | High : | 10.36 | Low : | 3.94 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ TKNO ] has closed below upper band by 40.4%. Bollinger Bands are 121.7% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 7 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.68 - 6.73 | 6.73 - 6.77 |
| Low: | 5.34 - 5.37 | 5.37 - 5.4 |
| Close: | 5.58 - 5.65 | 5.65 - 5.7 |
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
Thu, 25 Sep 2025
Alpha Teknova, Inc.'s (NASDAQ:TKNO) P/S Is Still On The Mark Following 27% Share Price Bounce - simplywall.st
Sat, 09 Aug 2025
Alpha Teknova, Inc. 2025 Q2 - Results - Earnings Call Presentation (NASDAQ:TKNO) 2025-08-09 - Seeking Alpha
Fri, 25 Jul 2025
Teknova to Report Second Quarter 2025 Financial Results on August 7, 2025 - The Manila Times
Thu, 24 Jul 2025
Critical Reagents Leader Teknova Sets Q2 Earnings Date: Key Updates Expected from Biotech Solutions Provider - Stock Titan
Wed, 11 Jun 2025
Shareholders Will Probably Not Have Any Issues With Alpha Teknova, Inc.'s (NASDAQ:TKNO) CEO Compensation - simplywall.st
Thu, 06 Mar 2025
Alpha Teknova, Inc. (NASDAQ:TKNO) Just Reported And Analysts Have Been Lifting Their Price Targets - simplywall.st
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 54 (M) |
| Shares Float | 10 (M) |
| Held by Insiders | 10.8 (%) |
| Held by Institutions | 85.2 (%) |
| Shares Short | 2,700 (K) |
| Shares Short P.Month | 2,760 (K) |
| EPS | -0.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.41 |
| Profit Margin | -55.3 % |
| Operating Margin | -33 % |
| Return on Assets (ttm) | -11.8 % |
| Return on Equity (ttm) | -27.8 % |
| Qtrly Rev. Growth | 7 % |
| Gross Profit (p.s.) | 0.17 |
| Sales Per Share | 0.72 |
| EBITDA (p.s.) | -0.28 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -9 (M) |
| Levered Free Cash Flow | -2 (M) |
| PE Ratio | -14.47 |
| PEG Ratio | 0 |
| Price to Book value | 3.97 |
| Price to Sales | 7.75 |
| Price to Cash Flow | -32.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|